Biogen Inc.
BIIBLast close · Oct 16, 2026232.65−2.70 (−1.15%)
Market cap$34.4B
Between Feb 6, 2026 and Oct 2, 2026, Biogen (BIIB) insiders filed 40 Form 4 transactions: 2 sales worth $239,749.9 in total and 1 open-market purchase worth $585.1; 2 of the sales were under 10b5-1 plans set in advance. The largest seller was Minor Lloyd, $120,580.6. 37 other filings were grants, exercises or gifts, which say nothing about buying or selling.
40
1
2
2
Form 4 transactions
| Date | Insider | Title | Code | Plan | Shares | Price | Value |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Godbout Sean | Chief Accounting Officer | M | 27 | 0.00 | $0 | |
| 2026-10-01 | Godbout Sean | Chief Accounting Officer | A | 985 | 0.00 | $0 | |
| 2026-10-02 | Godbout Sean | Chief Accounting Officer | F | 8 | 219.88 | $1,759 | |
| 2026-10-02 | Godbout Sean | Chief Accounting Officer | M | 27 | 0.00 | $0 | |
| 2026-09-01 | Parini Michael | Chief Legal Officer | A | 7,405 | 0.00 | $0 | |
| 2026-08-03 | Minor Lloyd | Director | S | 10b5-1 | 593 | 203.34 | $120,580.6 |
| 2026-08-04 | Minor Lloyd | Director | S | 10b5-1 | 593 | 200.96 | $119,169.3 |
| 2026-06-09 | HAWKINS WILLIAM A | Director | A | 1,505 | 0.00 | $0 | |
| 2026-06-09 | SHERWIN STEPHEN A | Director | A | 1,505 | 0.00 | $0 | |
| 2026-06-09 | Rowinsky Eric K | Director | A | 1,505 | 0.00 | $0 | |
| 2026-06-09 | Mantas Jesus B | Director | A | 1,505 | 0.00 | $0 | |
| 2026-06-09 | LANGER SUSAN | Director | A | 1,505 | 0.00 | $0 | |
| 2026-06-09 | Patolawala Monish D | Director | A | 1,505 | 0.00 | $0 | |
| 2026-06-09 | Pangalos Menelas N | Director | M | 2,370 | 0.00 | $0 | |
| 2026-06-09 | Pangalos Menelas N | Director | A | 1,505 | 0.00 | $0 | |
| 2026-06-09 | Pangalos Menelas N | Director | M | 2,370 | 0.00 | $0 | |
| 2026-06-09 | Minor Lloyd | Director | A | 1,505 | 0.00 | $0 | |
| 2026-06-09 | Freire Maria C | Director | A | 2,005 | 0.00 | $0 | |
| 2026-05-01 | Keeney Adam | Head of Corporate Development | M | 939 | 0.00 | $0 | |
| 2026-05-01 | Keeney Adam | Head of Corporate Development | F | 455 | 187.06 | $85,112.3 | |
| 2026-05-01 | Keeney Adam | Head of Corporate Development | M | 939 | 0.00 | $0 | |
| 2026-04-01 | Godbout Sean | Chief Accounting Officer | M | 181 | 0.00 | $0 | |
| 2026-04-01 | Godbout Sean | Chief Accounting Officer | F | 54 | 183.78 | $9,924.1 | |
| 2026-04-01 | Godbout Sean | Chief Accounting Officer | M | 181 | 0.00 | $0 | |
| 2026-02-13 | Viehbacher Christopher | President and CEO | A | 38,015 | 0.00 | $0 | |
| 2026-02-13 | Singhal Priya | Head of Development | A | 10,560 | 0.00 | $0 | |
| 2026-02-12 | Murphy Nicole | Head of Pharm Ops and Tech | P | 3 | 195.04 | $585.1 | |
| 2026-02-13 | Murphy Nicole | Head of Pharm Ops and Tech | A | 10,560 | 0.00 | $0 | |
| 2026-02-13 | Kramer Robin | Chief Financial Officer | A | 8,450 | 0.00 | $0 | |
| 2026-02-13 | Keeney Adam | Head of Corporate Development | A | 8,025 | 0.00 | $0 | |
| 2026-02-13 | Izzar Rachid | Head of Global Product Strat. | A | 7,390 | 0.00 | $0 | |
| 2026-02-13 | Grogan Jane | Head of Research | A | 8,450 | 0.00 | $0 | |
| 2026-02-13 | Gregory Ginger | EVP, Human Resources | A | 8,025 | 0.00 | $0 | |
| 2026-02-13 | Godbout Sean | Chief Accounting Officer | A | 1,800 | 0.00 | $0 | |
| 2026-02-13 | ALEXANDER SUSAN H | EVP Chief Legal Officer | A | 8,450 | 0.00 | $0 | |
| 2026-02-06 | Viehbacher Christopher | President and CEO | F | 4,356 | 201.18 | $876,340.1 | |
| 2026-02-06 | Viehbacher Christopher | President and CEO | M | 15,453 | 0.00 | $0 | |
| 2026-02-06 | Viehbacher Christopher | President and CEO | F | 6,624 | 201.18 | $1.3M | |
| 2026-02-06 | Viehbacher Christopher | President and CEO | M | 9,008 | 0.00 | $0 | |
| 2026-02-06 | Viehbacher Christopher | President and CEO | M | 9,008 | 0.00 | $0 |
Codes are the SEC's: P open-market purchase, S open-market sale; M exercise, F tax withholding, A grant and G gift are routine. A 10b5-1 flag means the trade ran under a plan adopted in advance. Method notes in where the numbers come from.